US2014199316A1PendingUtilityA1

Methods of treating complications and disorders associated with g-csf administration

61
Assignee: SACKSTEIN ROBERTPriority: May 5, 2011Filed: Jan 24, 2014Published: Jul 17, 2014
Est. expiryMay 5, 2031(~4.8 yrs left)· nominal 20-yr term from priority
Inventors:Robert Sackstein
A61K 2039/505C07K 16/40A61P 9/00A61K 39/3955
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) 2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for preventing and/or treating G-CSF-induced vascular complications and associated tissue damage comprising administering to a subject in need thereof a compound that inhibits the interaction between E-selectin receptor and MPO-EL, wherein the compound is administered in conjunction with G-CSF therapy. 
     
     
         2 . The method of  claim 1 , wherein the compound is an anti-MPO-EL antibody. 
     
     
         3 . The method of  claim 1 , wherein the compound is administered prior to, during or after administration of G-CSF. 
     
     
         4 . A method for preventing and/or treating vascular complications and associated tissue damage comprising administering to a subject in need thereof a compound that inhibits the interaction between E-selectin receptor and MPO-EL. 
     
     
         5 . The method of  claim 5 , wherein the compound that inhibits the interaction between E-selectin receptor and MPO-EL is an anti-MPO-EL antibody. 
     
     
         6 . The method of  claim 4 , wherein the vascular complication is sepsis. 
     
     
         7 . The method of  claim 4 , wherein the vascular complication is leukocytoclastic vasculitis. 
     
     
         8 . The method of  claim 4 , wherein the vascular complication is stroke. 
     
     
         9 . The method of  claim 4 , wherein the vascular complication is angina pectoris. 
     
     
         10 . The method of  claim 4 , wherein the vascular complication is myocardial infarct. 
     
     
         11 . The method of  claim 4 , wherein the vascular complication is a localized or systemic vasculitis syndromes. 
     
     
         12 . The method of  claim 4 , wherein the vascular complication is atherosclerosis. 
     
     
         13 . The method of  claim 4 , wherein the vascular complication is Wegener's granulomatosis. 
     
     
         14 . The method of  claim 4 , wherein the vascular complication is sickle cell crises. 
     
     
         15 . A method of treating acute myocardial infarction or other ischemic events in conjunction with reperfusion therapy comprising administering to a subject in need thereof a compound that inhibits the interaction between E-selectin receptor and MPO-EL. 
     
     
         16 . The method of  claim 15 , wherein the compound is an anti-MPO-EL antibody. 
     
     
         17 . The method of  claim 15 , wherein the reperfusion therapy is primary angioplasty.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.